Genomind®, a leading mental health care company, and NeuroFlow, a health care analytics and technology company, announced an agreement to partner their proprietary technology and clinical services to improve consumer care across a broad spectrum of mental health conditions. The collaboration will leverage NeuroFlow’s industry-leading mental health integration platform alongside Genomind Professional PGx Express™, one of the most comprehensive mental health pharmacogenomics service available. This novel partnership creates a new standard in mental health care by providing consumers and clinicians with actionable tools that support access to care, improve outcomes, and reduce costs in mental health treatment.
As part of the partnership, physicians using NeuroFlow’s IntegrateHealth™ application will be able to administer Genomind Professional PGx Express to their consumers and communicate results within the platform, including implications on treatment decisions. Physicians will now be able to seamlessly use Genomind’s service to help understand consumers’ genetics and how they may impact their mental health, and NeuroFlow’s technology applications to remotely monitor and track adherence and progress along the entire consumer journey. Clinicians who have already used Genomind Professional PGx Express will have the option to leverage NeuroFlow’s IntegrateHealth to risk stratify and remotely monitor their consumer populations by offering them access to NeuroFlow’s award-winning mobile application.
Genomind Professional PGx Express is designed to improve outcomes by helping clinicians navigate the complex connection between a consumer’s individual genetics and their implications on mental health care. The service provides genetic test results to physicians within three days of Genomind’s in-house lab receiving a consumer sample, with each sample tested twice to provide 99.9% accuracy. NeuroFlow’s software enables remote monitoring, risk stratification, and behavioral health integration across multiple medical care settings, including psychology, primary care, and pain management specialties.
Together, these tools facilitate measurement-based care, enabling doctors to proactively address their highest-cost consumers. Through new collaborative care codes, clinicians are now able to get reimbursed for these efforts to integrate behavioral health into their practice. The partnership between these two companies supports the goals of helping consumers recover while reducing overall costs of care and burden on the health care system.
Genomind is a leading mental health care company, delivering the genetic testing tools that empower clinicians to make more informed treatment decisions and create better outcomes for persons with mental illnesses. As a scientific leader in genetic testing, Genomind’s flagship offering is Genomind Professional PGx Express – the most comprehensive mental health genetic service available. Supported by a world-class genetics lab and unique consultative approach, Genomind is advancing a new paradigm of personalized medicine in mental health care.
NeuroFlow is a digital health company combining workflow automation, consumer engagement tools, and applied artificial intelligence to promote behavioral health integration in all care settings. NeuroFlow’s suite of HIPAA-compliant, cloud-based tools simplify remote consumer monitoring, improve risk stratification, and facilitate collaborative care. With NeuroFlow, care professionals can finally bridge the gap between mental and physical health in order to improve outcomes and reduce the cost of care.
This was reported by Genomind on August 19, 2019.
Contact information: Amy Pressman, Marketing Director, Genomind, 2200 Renaissance Boulevard, Suite 100, King of Prussia, Pennsylvania 19406; 877-895-8658; Email: firstname.lastname@example.org; Website: http://genomind.com
Contact information: Anthony Stipa, Public Relations Consultant, NeuroFlow, 1635 Market Street, Philadelphia, Pennsylvania 19103; 610-420-1724; Email: email@example.com; Website: www.neuroflowsolution.com; or Will Crowley, Marketing Manager, Neuroflow, 1635 Market Street, Philadelphia, Pennsylvania 19103; 610-608-3664; Email: firstname.lastname@example.org; Website: www.neuroflowsolution.com